Search Result

Results for "

MyD88

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MyD88 (12) Apoptosis (4) Autophagy (3) Bacterial (1) Beta-lactamase (1) Dynamin (2) FLT3 (2) HSP (2) IFNAR (1) Interleukin Related (1) IRAK (14) MAPKAPK2 (MK2) (1) Mitochondrial Metabolism (2) NF-κB (6) Potassium Channel (2) PROTACs (1) Reactive Oxygen Species (2) Small Interfering RNA (siRNA) (3) TNF Receptor (2) Toll-like Receptor (TLR) (12)
By Research Areas:	Cancer (18) Cardiovascular Disease (3) Infection (2) Inflammation/Immunology (31)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: MyD88

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149992

MyD88-IN-1	MyD88	Inflammation/Immunology Cancer
MyD88-IN-1 (Compound c17) is an orally active *MyD88* inhibitor. MyD88-IN-1 inhibits the interaction of TLR4 and MyD88 and suppressed the NF-κB pathway. MyD88-IN-1 can be used in research of cancer and inflammatory .

HY-139397

TJ-M2010-5 10+ Cited Publications	MyD88	Cardiovascular Disease
TJ-M2010-5 is a *MyD88* inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway . TJ-M2010-5 can be used for the research of myocardial ischemia/reperfusion injury (MIRI) .

HY-154438

RDR 02308	Beta-lactamase Toll-like Receptor (TLR) Bacterial	Inflammation/Immunology
RDR 02308 is a *TLR4-MyD88* binding inhibitor that inhibits full-length β-lactamase .

HY-50937

ST 2825 65+ Cited Publications	MyD88	Inflammation/Immunology
ST 2825 is a specific *MyD88* dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity .

HY-RS08886

MYD88 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MYD88 Human Pre-designed siRNA Set A contains three designed siRNAs for MYD88 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MYD88 Human Pre-designed siRNA Set A MYD88 Human Pre-designed siRNA Set A

HY-RS08887

Myd88 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Myd88 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Myd88 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Myd88 Mouse Pre-designed siRNA Set A Myd88 Mouse Pre-designed siRNA Set A

HY-RS08888

Myd88 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Myd88 Rat Pre-designed siRNA Set A contains three designed siRNAs for Myd88 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Myd88 Rat Pre-designed siRNA Set A Myd88 Rat Pre-designed siRNA Set A

HY-162863

*ERK-MYD88* interaction inhibitor 1**	Apoptosis	Cancer
ERK-MYD88 interaction inhibitor 1 is an ERK-MYD88 interaction inhibitor. ERK-MYD88 interaction inhibitor 1 can induce an HRI-mediated integrated stress response (ISR), leading to cancer cell-specific immunogenic cell apoptosis (apoptosis). ERK-MYD88 interaction inhibitor 1 can induce anti-tumor T cell responses in Lewis lung cancer mice, exhibiting anti-tumor activity .

HY-P10719

Pepinh-MYD	MyD88	Infection Inflammation/Immunology
Pepinh-MYD is a *MyD88* inhibitor that contains a domain sequence from MyD88 TIR and a protein transduction sequence, enabling it to penetrate the cell membrane. Pepinh-MYD interferes with *MyD88*-mediated TLR signaling pathways, thereby inhibiting related immune responses. It holds potential for studying the role of *MyD88* in viral infections .

HY-163775

Anti-inflammatory agent 88	MyD88 NF-κB	Inflammation/Immunology
Anti-inflammatory agent 88 (compound 6) is a carbazole derivative with anti-inflammatory activity found in marine Streptomyces. It exerts its anti-inflammatory effect by inhibiting pro-inflammatory factors and enhancing the expression of anti-inflammatory factors in the *Myd88/Nf-κB* pathway. Anti-inflammatory agent 88 can be used for the development of anti-inflammatory drugs .

HY-19744

T6167923 10+ Cited Publications	MyD88	Inflammation/Immunology
T6167923 is a selective inhibitor of MyD88-dependent signaling pathways. T6167923 directly binds to Toll/IL1 receptor (TIR) domain of MyD88 and disrupts MyD88 homodimeric formation. T6167923 inhibits NF-κB driven Staphylococcus enterotoxin AP (SEAP) activity, and improves anti-inflammatory activity with IC₅₀s of 2.7 μM, 2.9 μM, 2.66 μM and 2.66 μM for IFN-γ, IL-1β, IL-6 and TNF-α, respectively .

HY-Y0278

Chloranil Tetrachloro-p-benzoquinone	Toll-like Receptor (TLR) MyD88	Inflammation/Immunology
Chloranil activates the TLR4 signaling pathway by enhancing the expression of TLR4 and *MYD88*. Chloranil leads to neuroinflammation and cell damage .

HY-143486

IRAK4-IN-10	IRAK	Inflammation/Immunology Cancer
IRAK4-IN-10 (compound 75) is a potent IRAK4 inhibitor with an IC₅₀ of 1.5 nM. IRAK4-IN-10 blocks MyD88 dependent signaling. IRAK4-IN-9 has the potential for the research of inflammatory diseases, autoimmune diseases, and cancer .

HY-143485

IRAK4-IN-9	IRAK	Inflammation/Immunology Cancer
IRAK4-IN-9 (compound 73) is a potent IRAK4 inhibitor with an IC₅₀ of 1.5 nM. IRAK4-IN-9 blocks MyD88 dependent signaling. IRAK4-IN-9 has the potential for the research of inflammatory diseases, autoimmune diseases, and cancer .

HY-117066

CL075 2 Publications Verification 3M002	Toll-like Receptor (TLR)	Inflammation/Immunology
CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively .

HY-130253

IRAK4-IN-6	IRAK	Cancer
IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC₅₀ of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma .

HY-11109

Resatorvid Maximum Cited Publications 376 Publications Verification TAK-242; CLI-095	Toll-like Receptor (TLR) TNF Receptor Interleukin Related Autophagy	Inflammation/Immunology Cancer
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC_50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases .

HY-N0703

Schaftoside 4 Publications Verification	Toll-like Receptor (TLR) MyD88 Dynamin Mitochondrial Metabolism Autophagy	Inflammation/Immunology
Schaftoside is a flavonoid found in a variety of Chinese herbal medicines, such as Eleusine indica. Schaftoside inhibits the expression of TLR4 and Myd88. Schaftoside also decreases Drp1 expression and phosphorylation, and reduces mitochondrial fission .

HY-Y0278R

Chloranil (Standard)	Toll-like Receptor (TLR) MyD88	Inflammation/Immunology
Chloranil (Standard) is the analytical standard of Chloranil. This product is intended for research and analytical applications. Chloranil activates the TLR4 signaling pathway by enhancing the expression of TLR4 and MYD88. Chloranil leads to neuroinflammation and cell damage .

HY-146112

IRAK4-IN-14	IRAK	Cancer
IRAK4-IN-14 (compound 28) is a potent, selective and orally active IRAK4 inhibitor with an IC₅₀ of 0.003 µM. IRAK4-IN-14 shows good PK parameters in rats and mouse. IRAK4-IN-14 shows synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib .

HY-162004

NF-κB-IN-14	NF-κB Toll-like Receptor (TLR)	Inflammation/Immunology
NF-κB-IN-14 (compound 5e) significantly inhibits nitric oxide production in LPS-induced macrophages (IC₅₀: 6.4 μM). NF-κB-IN-14 disrupts the *TLR4-MyD88* protein interaction, leading to the suppression of the NF-κB signaling pathway suppression. NF-κB-IN-14 reduces ear edema and inflammation in an atopic dermatitis mouse model .

HY-146113

IRAK4-IN-15	IRAK	Cancer
IRAK4-IN-15 (compound 35) is a potent and selective IRAK4 inhibitor with an IC₅₀ of 0.002 µM. IRAK4-IN-15 shows good human PK predictions with low intrinsic clearance. IRAK4-IN-15 shows great synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib. .

HY-148274

KTX-582	PROTACs IRAK Apoptosis	Cancer
KTX-582 is a potent IRAK4 degrader with DC₅₀ values of 4 nM and 5 nM for IRAK4 and Ikaros, respectively. KTX-582 can induce apoptosis in MYD88 ^MT DLBCL, and is efficient to induce in vivo tumor regressions in lymphoma model .

HY-163035

EM-163	TNF Receptor IFNAR	Inflammation/Immunology
EM-163 is a summative BB-Loop analog. EM-163 can alleviate inflammation and prevent death from toxic shock by targeting the TIR domain of MyD88. EM-163 can be used in the study of SEB poisoning (SEB: Staphylococcal enterotoxin B) .

HY-P10718

IMG-2005	Toll-like Receptor (TLR)	Inflammation/Immunology
IMG-2005 is a TLR signaling pathway inhibitor. IMG-2005 mimics the Toll/interleukin-1 receptor (TIR) domain of MyD88, thereby preventing its homodimerization, which causes damage to tracheal epithelial cells and triggers pulmonary immune diseases .

HY-N0703R

Schaftoside (Standard)	Toll-like Receptor (TLR) MyD88 Dynamin Mitochondrial Metabolism Autophagy	Inflammation/Immunology
Schaftoside (Standard) is the analytical standard of Schaftoside. This product is intended for research and analytical applications. Schaftoside is a flavonoid found in a variety of Chinese herbal medicines, such as Eleusine indica. Schaftoside inhibits the expression of TLR4 and Myd88. Schaftoside also decreases Drp1 expression and phosphorylation, and reduces mitochondrial fission .

HY-164670

D228	Others	Inflammation/Immunology
D228 is an orally active antiinflammatory agent. D228 reduces ConA induced T lymphocyte cell proliferation (IC₅₀: 42.85 μM) and LPS induced B lymphocyte cell proliferation (IC₅₀: 3.15 μM). D228 is effective against inflammatory bowel disease (IBD). D228 alleviates the DSS (HY-116282C)-induced inflammation response in the IBD model by downregulating the MyD88/TRAF6/p38 signaling .

HY-155574

IRAK4-IN-27	IRAK Apoptosis	Cancer
IRAK4-IN-27 (Compound 22) is a potent, selective inhibitor of IRAK4, with IC₅₀ of 8.7 nM. IRAK4-IN-27 inhibits cell growth, and promotes apoptosis in MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line. IRAK4-IN-27 can be used for DLBCL study .

HY-N1934

Dihydroberberine	Potassium Channel HSP	Cardiovascular Disease Inflammation/Immunology Cancer
Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .

HY-W014223

2,4′-Dihydroxybenzophenone Ultraviolet absorber UV-0	Toll-like Receptor (TLR) Reactive Oxygen Species MyD88 IRAK NF-κB	Inflammation/Immunology
2,4′-Dihydroxybenzophenone (Ultraviolet absorber UV-0) occupies the hydrophobic pocket of MD2 and blocks the dimerization of TLR4. 2,4′-Dihydroxybenzophenone inhibits the LPS induced mtROS production, and LPS induced inflammatory response by downregulating pro-inflammatory mediators and decreasing the expression of MyD88, p-IRAK4, and NF-κB. 2,4′-Dihydroxybenzophenone is also a UV absorber .

HY-117622

ND-2110	IRAK	Inflammation/Immunology Cancer
ND-2110 is a selective IRAK4 inhibitor (K_i: 7.5 nM). ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations,. ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models .

HY-N1934R

Dihydroberberine (Standard)	Potassium Channel HSP	Cardiovascular Disease Inflammation/Immunology Cancer
Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .

HY-157793

SMU-L11	Toll-like Receptor (TLR) NF-κB MAPKAPK2 (MK2)	Inflammation/Immunology Cancer
SMU-L11 is a specific TLR7 agonist (EC₅₀=0.024 μM), which recruits MyD88 adapter protein and activates downstream NF-κB and MAPK signaling pathways. In murine models, SMU-L11 significantly enhances immune cell activation and promotes the proliferation of CD4 ⁺ T and CD8 ⁺ T cells, thereby directly killing tumor cells and inhibiting tumor growth. SMU-L11 can be used for cancer research, and also has the potential for studying immune system diseases .

HY-W014223R

2,4′-Dihydroxybenzophenone (Standard)	Toll-like Receptor (TLR) Reactive Oxygen Species MyD88 IRAK NF-κB	Inflammation/Immunology
2,4′-Dihydroxybenzophenone (Standard) is the analytical standard of 2,4′-Dihydroxybenzophenone. This product is intended for research and analytical applications. 2,4′-Dihydroxybenzophenone (Ultraviolet absorber UV-0) occupies the hydrophobic pocket of MD2 and blocks the dimerization of TLR4. 2,4′-Dihydroxybenzophenone inhibits the LPS induced mtROS production, and LPS induced inflammatory response by downregulating pro-inflammatory mediators and decreasing the expression of MyD88, p-IRAK4, and NF-κB. 2,4′-Dihydroxybenzophenone is also a UV absorber .

HY-N9541

Chaetoglobosin Vb	Others	Inflammation/Immunology
Chaetoglobosin Vb is a novel cytotoxic alkaloid with anti-inflammatory and antioxidant activities. Chaetoglobosin Vb can inhibit oxidative stress induced by LPS stimulation, reduce the production of reactive oxygen species and increase the expression of the antioxidant enzyme superoxide dismutase (SOD). Chaetoglobosin Vb significantly reduced the gene and protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) induced by LPS, and alleviated the production of proinflammatory cytokines such as TNF-α, IL-6 and IL-1β. Chaetoglobosin Vb exerts its biological activity through the TLR4-mediated MyD88-dependent signaling pathway and the TRIF-dependent signaling pathway, which is specifically manifested by inhibiting the phosphorylation of p38, ERK, and JNK MAPK and the translocation of NF-κB p65 subunit to the nucleus. Chaetoglobosin Vb showed no cytotoxic effect in the concentration range of 25-100 μM and promoted SOD enzyme activity and phosphorylation of p38, ERK1/2 and JNK in a dose-dependent manner .

HY-135317

Emavusertib 3 Publications Verification CA-4948	IRAK FLT3 Apoptosis	Inflammation/Immunology Cancer
Emavusertib (CA-4948) is a selective, potent and orally active IRAK4/FLT3 inhibitor. Emavusertib has an IC₅₀ of 57 nM for IRAK4 in a FRET kinase assay. Emavusertib shows anti-tumor activity .

HY-135317B

Emavusertib hydrochloride CA-4948 hydrochloride	IRAK FLT3	Inflammation/Immunology Cancer
Emavusertib (CA-4948) hydrochloride is a selective, potent and orally active IRAK4/FLT3 inhibitor. Emavusertib hydrochloride has an IC₅₀ of 57 nM for IRAK4 in a FRET kinase assay. Emavusertib hydrochloride shows anti-tumor activity .

HY-103017A

JH-X-119-01 3 Publications Verification	IRAK	Infection Inflammation/Immunology Cancer
JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice . JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC₅₀ of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM .

HY-150594

IRAK4-IN-17	IRAK NF-κB	Cancer
IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC₅₀ of 1.3 nM . IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research .

Cat. No.	Product Name

HY-L007

Immunology/Inflammation Compound Library	5,272 compounds
The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation. MCE designs a unique collection of 5,272 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

Immunology/Inflammation Compound Library

5,272 compounds

The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation.

MCE designs a unique collection of 5,272 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P3151

Gliadin p31-43	Peptides	Inflammation/Immunology
Gliadin p31-43 is an undigested gliadin peptide. Gliadin p31-43 induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 can be used for celiac disease research .

HY-P10719

Pepinh-MYD	MyD88	Infection Inflammation/Immunology
Pepinh-MYD is a *MyD88* inhibitor that contains a domain sequence from MyD88 TIR and a protein transduction sequence, enabling it to penetrate the cell membrane. Pepinh-MYD interferes with *MyD88*-mediated TLR signaling pathways, thereby inhibiting related immune responses. It holds potential for studying the role of *MyD88* in viral infections .

HY-P10178

Myristoylated ARF6 (2-13)	Peptides	Inflammation/Immunology
Myristoylated ARF6 (2-13) blocks MyD88–ARNO–ARF6–signaling axis by deactivating ARF6 .

HY-P10718

IMG-2005	Toll-like Receptor (TLR)	Inflammation/Immunology
IMG-2005 is a TLR signaling pathway inhibitor. IMG-2005 mimics the Toll/interleukin-1 receptor (TIR) domain of MyD88, thereby preventing its homodimerization, which causes damage to tracheal epithelial cells and triggers pulmonary immune diseases .

HY-P3151A

Gliadin p31-43 TFA	Peptides	Inflammation/Immunology
Gliadin p31-43 TFA is an undigested gliadin peptide. Gliadin p31-43 TFA induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 TFA can be used for celiac disease research .

Species:	Human (2)
Tag:	His (1) Tag Free (1) GST (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P702056

	MYD88 Protein, Human MyD88; Myeloid differentiation primary response protein MyD88	Human	E. coli
	The MYD88 protein is a key adapter in Toll-like receptor (TLR) and IL-1 receptor signaling and can activate NF-kappa-B, cytokine secretion and inflammatory responses through IRAK1, IRAK2, IRF7 and TRAF6. It enhances IL-8 transcription and participates in IL-18-mediated pathways. MYD88 Protein, Human is the recombinant human-derived MYD88 protein, expressed by E. coli , with tag free. The total length of MYD88 Protein, Human is 140 a.a., .

HY-P702057

	MYD88 Protein, Human (His, GST) MyD88; Myeloid differentiation primary response protein MyD88	Human	E. coli
	The MYD88 protein is a key adapter in Toll-like receptor (TLR) and IL-1 receptor signaling and can activate NF-kappa-B, cytokine secretion and inflammatory responses through IRAK1, IRAK2, IRF7 and TRAF6. It enhances IL-8 transcription and participates in IL-18-mediated pathways. MYD88 Protein, Human (His, GST) is the recombinant human-derived MYD88 protein, expressed by E. coli , with N-6*His, N-GST labeled tag. The total length of MYD88 Protein, Human (His, GST) is 140 a.a., .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80760

	MyD88 Antibody MyD88; Myeloid differentiation primary response protein MyD88	ICC/IF, WB, IHC-F, IHC-P, ELISA	Human, Mouse, Rat
	MyD88 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 33 kDa, targeting to MyD88. It can be used for ICC/IF,WB,IHC-F,IHC-P,ELISA assays with tag free, in the background of Human, Mouse, Rat.

HY-P80233

	MyD88 Antibody (YA280)	WB, ICC/IF, IHC-P, FC	Human
	MyD88 Antibody (YA280) is a non-conjugated and Rabbit origined monoclonal antibody about 33 kDa, targeting to MyD88. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human.

HY-P82518

	TRIF Antibody (YA2263) TRIF; IIAE6; MyD88-3; PRVTIRB; TICAM-1	WB, IP	Human, Mouse, Rat
	TRIF Antibody (YA2263) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2263), targeting TRIF, with a predicted molecular weight of 76 kDa (observed band size: 98 kDa). TRIF Antibody (YA2263) can be used for WB, IP experiment in human, mouse, rat background.